PGPrecigen, Inc. PGEN · NASDAQ
$6.66 +4.23% (+$0.27)
- Market cap
- $2.38B
- Enterprise value
- $2.47B
- P/E
- -
- Forward P/E
- 43.8x
- PEG
- -
- P/S
- 27.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -27.8%
- Gross margin
- 89.6%
- Net margin
- -184.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.92
- Free float
- 45.9%
About the company
Precigen, Inc. (PGEN) is a biotechnology company focused on the development and commercialization of advanced therapeutic and diagnostic technologies. The company specializes in genome engineering and genetic manipulation, enabling the development of novel drugs and diagnostic tools for the treatment and detection of various diseases. Their technologies include CRISPR-Cas9 and other genome editing tools, gene therapy, immunotherapy, and genetic analysis-based diagnostic tests.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Sabzevari
Employees
160
Headquarters
Germantown
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number